A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...
Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
The FDA approved a phase 3 trial for iSCIB1+ in advanced melanoma, focusing on progression-free survival as a surrogate endpoint. Phase 2 SCOPE trial showed a 24% improvement in progression-free ...
The FDA approved the IND application for a phase 3 trial of iSCIB1+ in advanced melanoma, starting in 2026. iSCIB1+ showed significant improvement in progression-free survival and overall survival in ...
Both dosage regimens of amlitelimab were associated with statistically significant improvements in skin clearance and disease severity vs placebo in the US estimand. Topline data were announced from ...
The U.S. Space Force has awarded SpaceX nine task orders worth $739 million combined to provide Lane 1 launch services under the National Security Space Launch, or NSSL, program’s third phase. The ...
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...
Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
(RTTNews) - Eli Lilly and Company (LLY) announced updated results from the Phase 3 EMBER-3 study evaluating Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen ...
(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results